Developing biomarkers to predict benefit from HGF/MET pathway inhibitors

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 210-218

  Koeppen, Hartmut ^a   Rost, Sandra ^a   Yauch, Robert L ^a  

^a GENENTECH INC   (United States)

Author keywords

companion diagnostic; HGF; MET; pathway; signalling

Indexed keywords

ANTINEOPLASTIC AGENT; ATK 701; BEVACIZUMAB; BIOLOGICAL MARKER; CABOZANTINIB; CRIZOTINIB; EMD 1204831; EMD 1214063; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; HYBRID PROTEIN; INCB 028060; K RAS PROTEIN; LY 2875358; MITOXANTRONE; MONOCLONAL ANTIBODY; ONARTUZUMAB; PANITUMUMAB; PLASMINOGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; TAK 701; TIVANTINIB; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE LOCUS; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIGAND BINDING; LIVER CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOCYTE; METASTASIS; MISSENSE MUTATION; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OSTEOSARCOMA CELL; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SCORING SYSTEM; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION; STOMACH CANCER; SURVIVAL RATE; THYROID CANCER; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; WILD TYPE;

COMPANION DIAGNOSTIC; HGF; MET; PATHWAY; SIGNALLING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG DISCOVERY; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 84890283023     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4268     Document Type: Review

References (66)

1. Cooper CS, Park M, Blair DG, et al., Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 29-33.
2. Trusolino L, Bertotti A, Comoglio PM,. MET signalling: principles and functions in development, organ regeneration and cancer. Nature Rev Mol Cell Biol 2010; 11: 834-848.
3. Peters S, Adjei AA,. MET: a promising anticancer therapeutic target. Nature Rev Clin Oncol 2012; 9: 314-326.
4. Sierra JR, Tsao MS,. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3 (1 Suppl): S21-S35.
5. Arriola E, Canadas I, Arumi-Uria M, et al., MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer 2011; 105: 814-823.
6. Okuda K, Sasaki H, Yukiue H, et al., Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008; 99: 2280-2285.
7. Park S, Choi Y-L, Sung CO, et al., High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012; 27: 197-207.
8. De Oliveira ATT, Matos D, Logullo AF, et al., MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009; 29: 4807-4811.
9. Zagouri F, Bago-Horvath Z, Roessler F, et al., High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013; 19: 1-6.
10. Graziano, F, Gallucio N, Lorenzini P, et al., Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789-4795.
11. Yamashita J, Ogawa M, Yamashita S, et al., Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54: 1630-1633.
12. Camp RL, Rimm EB, Rimm DL,. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999; 86: 2259-2265.
13. Kammula US, Kuntz EJ, Francone TD, et al., Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumour stage and clinical outcome. Cancer Lett 2007; 248: 219-228.
14. Ueki T, Fujimoto J, Suzuki T, et al., Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997; 25: 862-866.
15. Cheng HL, Trink B, Tzai TS, et al., Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002; 20: 1544-1550.
16. Tsai HW, Chow NH, Lin CP, et al., The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol 2006; 37: 198-204.
17. Dziadziuszko R, Wynes MW, Singh S, et al., Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012; 7: 340-347.
18. Masuya D, Huang C, Liu D, et al., The tumour-stromal interaction between intratumoural c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004; 90: 1555-1562.
19. Sun W, Song L, Ai T, et al., Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J Biomed Res 2013; 27: 220-230.
20. Lubensky IA, Schmidt L, Zhuang Z, et al., Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999; 155: 517-526.
21. Park WS, Dong SM, Kim SY, et al., Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59: 307-310.
22. Michieli P, Basilico C, Pennacchietti S, et al., Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999; 18: 5221-5231.
23. Graveel C, Su Y, Koeman J, et al., Activating Met mutations produce unique tumour profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 2004; 101: 17198-17203.
24. Ponzo MG, Lesurf R, Petkiewicz S, et al., Met induces mammary tumours with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009; 106: 12903-12908.
25. Kong-Beltran M, Seshagiri S, Zha J, et al., Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res 2006; 66: 283-289.
26. Tyner JW, Fletcher LB, Wang EQ, et al., MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010; 70: 6233-6237.
27. Toschi L, Cappuzzo F,. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010; 6: 239-247.
28. Smolen G, Sordella R, Muir B, et al., Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006; 103: 2316-2321.
29. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
30. Turke AB, Zejnullahu K, Wu Y-L, et al., Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
31. Bottaro DP, Rubin JS, Faletto DL, et al., Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
32. Nakamura T, Sakai K, Nakamura T, et al., Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011; 26: 188-202.
33. Seidel C, Lenhoff S, Brabrand S, et al., Hepatocyte growth factor in multiple myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002; 119: 672-676.
34. Barreiros AP, Sprinzl M, Rosset S, et al., EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes. Int J Cancer 2009; 124: 120-129.
35. Okamoto T, Takatsuka H, Fujimori Y, et al., Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant 2001; 28: 197-200.
36. Yamada T, Hisanaga M, Nakajima Y, et al., Serum interleukin-6, interleukin-8, hepatocyte growth factor, and nitric oxide changes during thoracic surgery. World J Surg 1998; 22: 783-790.
37. Xie Q, Bradley R, Kang L, et al., Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 2012; 109: 570-575.
38. Wilson TR, Fridlyand J, Yan Y, et al., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
39. Straussman R, Morikawa T, Shee K, et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500-504.
40. Kentsis A, Reed C, Rice KL, et al., Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature Med 2012; 18: 1118-1122.
41. Catenacci DVT, Henderson L, Xiao SY, et al., Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011; 1: 573-579.
42. Spigel DR, Ervin TJ, Ramlau R, et al., Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011; 29: 7505.
43. Penuel E, Li C, Parab V, et al., HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumours. Mol Cancer Ther 2013; 12: 1122-1130.
44. Goldman JW, Rosen LS, Algazi AP, et al., First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer. J Clin Oncol 2013; 31: 8093.
45. Burgess TL, Sun J, Meyer S, et al., Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010; 9: 400-409.
46. Gordon MS, Sweeney CJ, Mendelson DS, et al., Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumours. Clin Cancer Res 2010; 16: 699-710.
47. Ryan CJ, Rosenthal M, Ng S, et al., Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res 2013; 19: 215-224.
48. Wen PY, Schiff D, Cloughesy TF, et al., A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncology 2011; 13: 437-446.
49. Eng C, Van Cutsem E, Nowara E, et al., A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): primary and biomarker analyses. J Clin Oncol 2011; 29: 3500.
50. Oliner K, Tang R, Anderson A, et al., Evaluation of MET-pathway biomarkers in a phase 2 study of rilotumumab plus epirubicin, cisplatin, and capecetabine in gastric/esophagogastric junction cancer. Ann Oncol 2012; 23: iv8.
51. Mok TSK, Park K, Geater SL, et al., A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor inhibitory MAB, in combination with gefitinib versus gefitinib in Asian patients with lung adenocarcinoma. Ann Oncol 2012; 23: ix389-ix399.
52. Okamoto W, Okamoto I, Tanaka K, et al., TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumour-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9: 2785-2792.
53. Ou SHI,. Crizotinib: a-novel-and-first-in-class-multi-targeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer. Drug Design 2011; 5: 471-485.
54. Lennerz JK, Kwak EL, Ackerman A, et al., MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803-4810.
55. Chi AS, Batchelor TT, Kwak EL, et al., Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012; 30: 30-33.
56. Okamoto W, Okamoto I, Arao T, et al., Antitumour action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012; 11: 1557-1564.
57. Kurzrock R, Sherman SI, Ball DW, et al., Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29: 2660-2666.
58. Katayama R, Aoyama A, Yamori T, et al., Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013; 73: 3087-3096.
59. Basilico C, Pennacchietti S, Vigna E, et al., Tivantinib (ARQ 197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013; 19: 2381-2392.
60. Sequist LV, Pawel von J, Garmey EG, et al., Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-3315.
61. Santoro A, Porta C, Rimassa L, et al., Metiv-HCC: a phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). J Clin Oncol 2013; 31: TPS4159.
62. Choueiri TK, Vaishampayan U, Rosenberg JE, et al., Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31: 181-186.
63. Shah MA, Wainberg ZA, Catenacci DT, et al., Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013; 8: e54014.
64. Oliner K, Tang R, Anderson A, et al., Evaluation of MET-pathway biomarkers in a phase 2 study of rilotumumab or placebo in combination with epirubicin, cisplatin, and capecetabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. J Clin Oncol 2012; 30: 4005.
65. Simeon-Dubach D, Burt AD, Hall PA,. Quality really matters: the need to improve specimen quality in biomedical research. Histopathology 2012; 61: 1003-1005.
66. Hicks DG, Schiffhauer L,. Standardized assessment of the HER2 status in breast cancer by immunohistochemistry. Lab Med 2011; 42 003A 459-467.